August 6, 2020 by BJP · Published August 6, 2020 · Last modified March 7, 2021 AT845: Audentes Therapeutics Begins Recruiting Patients for new Phase 1/2 LOPD Gene Therapy Clinical Trial for Pompe Disease (FORTIS)
July 29, 2020 by BJP · Published July 29, 2020 · Last modified March 7, 2021 Higher dosing of alglucosidase alfa (ERT) improves outcomes in children with Pompe disease: a clinical study and review of the literature
July 29, 2020 by BJP · Published July 29, 2020 · Last modified August 8, 2020 Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study
July 29, 2020 by BJP · Published July 29, 2020 · Last modified March 7, 2021 Actus-101 Gene Therapy Promising Early Results (Phase 1/2 study of AAV2/8-LSPhGAA in Late-Onset Pompe Disease)
July 22, 2020 by BJP · Published July 22, 2020 · Last modified March 7, 2021 Effects of higher and more frequent dosing of alglucosidase alfa (40mg/kg/week ERT dose) and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
July 19, 2020 by BJP · Published July 19, 2020 · Last modified August 8, 2020 Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start
July 19, 2020 by BJP · Published July 19, 2020 · Last modified March 7, 2021 Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease
